Response Genetics Expands Sales Force to Cover Major National Oncology Markets and Meet Higher Demand for its ResponseDX Tests

Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, announced today it will triple the size of its sales force to meet higher demand for its ResponseDX™ genetic testing services.

Since their launch in September 2008, more than 500 ResponseDX: Lung™ and ResponseDX: Colon™ tests have been sold, exceeding the company’s initial sales goal. The company has also experienced a reorder rate of more than 90 percent. As a result of this initial rapid adoption, Response Genetics has decided to increase its sales force, which initially focused on the California market, to begin serving most major national markets.

SeraCare Life Sciences, Inc. (NASDAQ: SRLS) launched the Company’s anticipated genetic controls business with the introduction of two new products at the Association for Molecular Pathology 2008 Annual Meeting. Initial products launched include ACCURUN^® 601 controls for diagnostic testing of warfarin sensitivity and ACCURUN^® 610 controls for thrombophilia testing, which were developed internally by SeraCare. Additionally, the Company announced that it has entered into an exclusive licensing and technology transfer agreement with Sacred Heart Medical Center & Children’s Hospital, Spokane, WA, which allows SeraCare to manufacture and distribute additional controls for genetic testing, including screening for cystic fibrosis and for diseases common among people of Ashkenazi Jewish ancestry, under patents and proprietary know-how owned by Sacred Heart.

Amorfix vCJD assay achieves 100% sensitivity and 100% specificity on 1,000 fresh samples from UK blood donors

Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases, today announced the best sensitivity and specificity ever reported using its EP-vCJDTM Blood Screening Assay to test fresh blood plasma samples from anonymous UK blood donors. Amorfix completed this testing in the laboratories of the National Institute for Biological Standards and Control (NIBSC) in the United Kingdom.

Amorfix tested 1,000 fresh blinded human plasma samples which included samples that were spiked with vCJD brain prions and normal brain. The EP- vCJDTM Blood Screening Assay scored 100% sensitivity for all spiked samples down to a 1 in 100,000 dilution of 10% brain homogenate (1/1,000,000 dilution of vCJD brain). The specificity for all samples was 99.3% on initial testing and 100% on repeat reactive testing.

DIAGNOS Launches its New CARA (Computer Aided Retinal Analysis) Application and Signs the First Canadian Reseller for Ontario

DIAGNOS inc. ("DIAGNOS" or the "Corporation") (TSX VENTURE: ADK), a leader in the use of artificial intelligence ("AI") and advanced knowledge extraction techniques, launches CARA (Computer Aided Retinal Analysis) application bringing to market an 18 month development effort. CARA is an automated system for the identification of diabetic retinopathy and other eye related pathologies.

"I am very pleased to announce this new development based on our Artificial Intelligence platform. The software will be used for screening patients in hospitals, as well as private and public clinics and practices. The World Health Organization estimates that by year 2030, 366,000,000 people will have diabetes.